{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"ALDX","limit":50},"count":50,"signals":[{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":", and the ability to serve those markets; the rate and degree of market acceptance of any of reproxalap or any of our other product candidates following regulatory approval, if any; the timing of enrollment, commencement, and completion of our clinical trials;  the timing and success of preclinical studies and clinical trials conducted by us and our development partners; the risk that prior results,","filed_date":"2026-02-27","accession":"0001193125-26-083012","full_text":"https://origin.rootz.global/static/filing/0001193125-26-083012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":70,"context":"y regulatory approval of reproxalap, once obtained, may be withdrawn. Ultimately, the failure to obtain and maintain regulatory approvals would prevent reproxalap from being marketed and would have a material adverse effect on our business. The FDAs shift toward radical transparency, including plans to release future complete response letters promptly after they are issued to sponsors, could have an adverse impact on ou","filed_date":"2026-02-27","accession":"0001193125-26-083012","full_text":"https://origin.rootz.global/static/filing/0001193125-26-083012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ation thereto) plus 3.10% to the greater of (x) the Prime Rate (as defined therein) plus 3.10% or (y) 8.60%. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, was to commence upon expiration of the interest-only period and continue through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB","filed_date":"2025-11-05","accession":"0001193125-25-266989","full_text":"https://origin.rootz.global/static/filing/0001193125-25-266989.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"ntrol, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Companys ability to utilize some or all NOLs or credits could have a material adverse effect on the Companys results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that the aggregate Section 382","filed_date":"2025-11-05","accession":"0001193125-25-266989","full_text":"https://origin.rootz.global/static/filing/0001193125-25-266989.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, was to commence upon expiration of the interest-only period and continue through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB","filed_date":"2025-08-07","accession":"0000950170-25-104971","full_text":"https://origin.rootz.global/static/filing/0000950170-25-104971.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"ntrol, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Companys ability to utilize some or all NOLs or credits could have a material adverse effect on the Companys results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that the aggregate Section 382","filed_date":"2025-08-07","accession":"0000950170-25-104971","full_text":"https://origin.rootz.global/static/filing/0000950170-25-104971.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, was to commence upon expiration of the interest-only period and continue through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB","filed_date":"2025-05-14","accession":"0000950170-25-071602","full_text":"https://origin.rootz.global/static/filing/0000950170-25-071602.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"ntrol, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Companys ability to utilize some or all NOLs or credits could have a material adverse effect on the Companys results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that the aggregate Section 382","filed_date":"2025-05-14","accession":"0000950170-25-071602","full_text":"https://origin.rootz.global/static/filing/0000950170-25-071602.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"director, chair, member of a committee, or chair of a committee, as applicable. | | |  (3) |  The initial equity grant upon election or appointment as a director shall vest in three equal annual installments following the grant date. | | |  (4) |  Each initial equity grant shall be pro-rated for the number of whole months remaining until the anniversary of the stockholder meeting for the prior year,","filed_date":"2025-04-25","accession":"0001193125-25-096899","full_text":"https://origin.rootz.global/static/filing/0001193125-25-096899.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":46,"context":"C. as Aldeyra Therapeutics, Inc.s independent registered public accounting firm for the year ending December31, 2025. Proposal 3: To approve, on a non-binding, advisory basis, the compensation of our named executive officers as described in this proxy statement. To transact such other business as may properly come before the annual meeting or any adjournment thereof. These items of business are more fully described in t","filed_date":"2025-04-25","accession":"0001193125-25-096899","full_text":"https://origin.rootz.global/static/filing/0001193125-25-096899.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"and the ability to serve those markets;  the rate and degree of market acceptance of any of reproxalap or any of our other product candidates following regulatory approval, if any; the timing of enrollment, commencement, and completion of our clinical trials;  the timing and success of preclinical studies and clinical trials conducted by us and our development partners;  the risk that prior results,","filed_date":"2025-02-28","accession":"0000950170-25-030102","full_text":"https://origin.rootz.global/static/filing/0000950170-25-030102.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":67,"context":"ay approval, if any, of the Resubmitted NDA. Any such requirement would increase our costs and delay approval and commercialization of reproxalap for the treatment of dry eye disease and would have a material adverse effect on our business and financial condition. Additionally, the FDA has substantial discretion in  34 the approval process and may disagree with our interpretation of, or the sufficiency of, the data from","filed_date":"2025-02-28","accession":"0000950170-25-030102","full_text":"https://origin.rootz.global/static/filing/0000950170-25-030102.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the interest-only period and continues through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB ASC T","filed_date":"2024-11-07","accession":"0000950170-24-123248","full_text":"https://origin.rootz.global/static/filing/0000950170-24-123248.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"ntrol, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Companys ability to utilize some or all NOLs or credits could have a material adverse effect on the Companys results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that the aggregate Section 382","filed_date":"2024-11-07","accession":"0000950170-24-123248","full_text":"https://origin.rootz.global/static/filing/0000950170-24-123248.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the interest-only period and continues through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB ASC T","filed_date":"2024-08-01","accession":"0000950170-24-089238","full_text":"https://origin.rootz.global/static/filing/0000950170-24-089238.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"l, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Companys ability to utilize some or all its NOLs or credits could have a material adverse effect on the Companys results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that its aggregate Section 382","filed_date":"2024-08-01","accession":"0000950170-24-089238","full_text":"https://origin.rootz.global/static/filing/0000950170-24-089238.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"ration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the interest-only period and continues through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB ASC T","filed_date":"2024-05-02","accession":"0000950170-24-052056","full_text":"https://origin.rootz.global/static/filing/0000950170-24-052056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"l, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Companys ability to utilize some or all its NOLs or credits could have a material adverse effect on the Companys results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that its aggregate Section 382","filed_date":"2024-05-02","accession":"0000950170-24-052056","full_text":"https://origin.rootz.global/static/filing/0000950170-24-052056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"director, chair, member of a committee, or chair of a committee, as applicable. | | |  (3) |  The initial equity grant upon election or appointment as a director shall vest in three equal annual installments following the grant date. | | |  (4) |  Each initial equity grant shall be pro-rated for the number of whole months remaining until the anniversary of the prior years stockholders meeting, rounde","filed_date":"2024-04-22","accession":"0001193125-24-104862","full_text":"https://origin.rootz.global/static/filing/0001193125-24-104862.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":31,"context":". as Aldeyra Therapeutics, Inc.s independent registered public accounting firm for the year ending December 31, 2024. Proposal 3: To approve, on a non-binding, advisory basis, the compensation of our named executive officers as described in this proxy statement.  To transact such other business as may properly come before the annual meeting or any adjournment thereof. These items of business are more fully described in","filed_date":"2024-04-22","accession":"0001193125-24-104862","full_text":"https://origin.rootz.global/static/filing/0001193125-24-104862.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"and the ability to serve those markets;  the rate and degree of market acceptance of any of reproxalap or any of our other product candidates following regulatory approval, if any; the timing of enrollment, commencement, and completion of our clinical trials;  the timing and success of preclinical studies and clinical trials conducted by us and our development partners;  the risk that prior results,","filed_date":"2024-03-07","accession":"0000950170-24-027933","full_text":"https://origin.rootz.global/static/filing/0000950170-24-027933.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":63,"context":"if any, of a potential NDA resubmission. Any such requirement would increase our costs and delay approval and commercialization of reproxalap for the treatment of  33 dry eye disease and would have a material adverse effect on our business and financial condition. Additionally, the FDA has substantial discretion in the approval process and may disagree with our interpretation of or the sufficiency of the data from our c","filed_date":"2024-03-07","accession":"0000950170-24-027933","full_text":"https://origin.rootz.global/static/filing/0000950170-24-027933.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"of the aggregate amount of advances under the Loan and Security Agreement, and was paid on October 2, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences in May 2024 upon expiration of the interest-only period and continues through the Maturity Date, as amended. The Second Amendment was determined to be a modification in accordance with","filed_date":"2023-11-03","accession":"0000950170-23-058829","full_text":"https://origin.rootz.global/static/filing/0000950170-23-058829.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Company&#x2019;s ability to utilize some or all its NOLs or credits could have a material adverse effect on the Company&#x2019;s results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that its aggregate Sec","filed_date":"2023-11-03","accession":"0000950170-23-058829","full_text":"https://origin.rootz.global/static/filing/0000950170-23-058829.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"October 1, 2023 or (B) repayment of the aggregate amount of advances under the Loan and Security Agreement. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences in May 2024 upon expiration of the interest-only period and continues through the Maturity Date, as amended. The Second Amendment was determined to be a modification in accordance with","filed_date":"2023-08-03","accession":"0000950170-23-037934","full_text":"https://origin.rootz.global/static/filing/0000950170-23-037934.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Company&#x2019;s ability to utilize some or all its NOLs or credits could have a material adverse effect on the Company&#x2019;s results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that its aggregate Sec","filed_date":"2023-08-03","accession":"0000950170-23-037934","full_text":"https://origin.rootz.global/static/filing/0000950170-23-037934.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":28,"context":"director, chair, member of a committee, or chair of a committee, as applicable. | | |  (3) |  The initial equity grant upon election or appointment as a director shall vest in three equal annual installments following the grant date. | | |  (4) |  Each initial equity grant shall be pro-rated for the number of whole months remaining until the anniversary of the prior years stockholders meeting, rounde","filed_date":"2023-05-23","accession":"0001193125-23-151833","full_text":"https://origin.rootz.global/static/filing/0001193125-23-151833.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":33,"context":"ra Therapeutics, Inc.s independent registered public accounting firm for the year ending December 31, 2023. | | |  |  Proposal 3: To approve, on a non-binding, advisory basis, the compensation of our named executive officers as described in this proxy statement. | | |  |  Proposal 4: To approve the adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan (the 2023 Equity Incentive Plan) as described in this","filed_date":"2023-05-23","accession":"0001193125-23-151833","full_text":"https://origin.rootz.global/static/filing/0001193125-23-151833.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the interest-only period and continues through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB ASC T","filed_date":"2023-05-04","accession":"0000950170-23-017827","full_text":"https://origin.rootz.global/static/filing/0000950170-23-017827.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Company&#x2019;s ability to utilize some or all its NOLs or credits could have a material adverse effect on the Company&#x2019;s results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that its aggregate Sec","filed_date":"2023-05-04","accession":"0000950170-23-017827","full_text":"https://origin.rootz.global/static/filing/0000950170-23-017827.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"ose markets;  &#x2022; the rate and degree of market acceptance of any of reproxalap, ADX-2191 or any of our other product candidates following regulatory approval, if any; &#x2022; the timing of enrollment, commencement, and completion of our clinical trials;  &#x2022; the timing and success of preclinical studies and clinical trials conducted by us and our development partners;  &#x2022; the risk t","filed_date":"2023-03-09","accession":"0000950170-23-006998","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006998.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"her charges and expenses for products that fail to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives.  Issues with product quality could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products. Our success depends upon the quality of our products. Quality controls, assurance, a","filed_date":"2023-03-09","accession":"0000950170-23-006998","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006998.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the interest-only period and continues through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB ASC T","filed_date":"2022-11-10","accession":"0000950170-22-024434","full_text":"https://origin.rootz.global/static/filing/0000950170-22-024434.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Company&#x2019;s ability to utilize some or all its NOLs or credits could have a material adverse effect on the Company&#x2019;s results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that its aggregate Sec","filed_date":"2022-11-10","accession":"0000950170-22-024434","full_text":"https://origin.rootz.global/static/filing/0000950170-22-024434.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the interest-only period and continues through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB ASC T","filed_date":"2022-08-05","accession":"0000950170-22-015115","full_text":"https://origin.rootz.global/static/filing/0000950170-22-015115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Company&#x2019;s ability to utilize some or all its NOLs or credits could have a material adverse effect on the Company&#x2019;s results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that its aggregate Sec","filed_date":"2022-08-05","accession":"0000950170-22-015115","full_text":"https://origin.rootz.global/static/filing/0000950170-22-015115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"ration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the interest-only period and continues through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB ASC T","filed_date":"2022-05-05","accession":"0000950170-22-007890","full_text":"https://origin.rootz.global/static/filing/0000950170-22-007890.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Company&#x2019;s ability to utilize some or all its NOLs or credits could have a material adverse effect on the Company&#x2019;s results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that its aggregate Sec","filed_date":"2022-05-05","accession":"0000950170-22-007890","full_text":"https://origin.rootz.global/static/filing/0000950170-22-007890.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"director, chair, member of a committee, or chair of a committee, as applicable. | | |  (3) |  The initial equity grant upon election or appointment as a director shall vest in three equal annual installments following the grant date. | | |  (4) |  Each initial equity grant shall be pro-rated for the number of whole months remaining until the anniversary of the prior years stockholders meeting, rounde","filed_date":"2022-04-25","accession":"0001193125-22-117585","full_text":"https://origin.rootz.global/static/filing/0001193125-22-117585.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":28,"context":"ra Therapeutics, Inc.s independent registered public accounting firm for the year ending December 31, 2022. | | |  |  Proposal 3: To approve, on a non-binding, advisory basis, the compensation of our named executive officers as described in this proxy statement. | | |  |  To transact such other business as may properly come before the annual meeting or any adjournment thereof. | | |  |  These items of business are more","filed_date":"2022-04-25","accession":"0001193125-22-117585","full_text":"https://origin.rootz.global/static/filing/0001193125-22-117585.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"ld differ materially from those projected in our forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to:  &#x2022; the timing of enrollment, commencement, and completion of our clinical trials;  &#x2022; the timing and success of preclinical studies and clinical trials conducted by us and our development partners;  &#x2022; delay in o","filed_date":"2022-03-17","accession":"0000950170-22-004111","full_text":"https://origin.rootz.global/static/filing/0000950170-22-004111.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"r application approvable. Even if the NDA is accepted for filing by the FDA, there can be no assurance that it would be approved in a timely manner or at all. Issues with product quality could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products. Our success depends upon the quality of our products. Quality controls, assurance, a","filed_date":"2022-03-17","accession":"0000950170-22-004111","full_text":"https://origin.rootz.global/static/filing/0000950170-22-004111.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the  12 interest-only period and continues through October 1, 2023 (the &#x201c;Maturity Date&#x201d;). The First Amendment was determined to be a modification in ac","filed_date":"2021-10-28","accession":"0000950170-21-002456","full_text":"https://origin.rootz.global/static/filing/0000950170-21-002456.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Company&#x2019;s ability to utilize some or all its NOLs or credits could have a material adverse effect on the Company&#x2019;s results of operations and cash flows. Prior to December 31, 2017, the Company believes it underwent three ownership changes, however, management believes there are sufficient","filed_date":"2021-10-28","accession":"0000950170-21-002456","full_text":"https://origin.rootz.global/static/filing/0000950170-21-002456.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the  12 interest-only period and continues through October 1, 2023 (the &#x201c;Maturity Date&#x201d;). The First Amendment was determined to be a modification in ac","filed_date":"2021-08-05","accession":"0000950170-21-000925","full_text":"https://origin.rootz.global/static/filing/0000950170-21-000925.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Company&#x2019;s ability to utilize some or all its NOLs or credits could have a material adverse effect on the Company&#x2019;s results of operations and cash flows. Prior to December 31, 2017, the Company believes it underwent three ownership changes, however, management believes there are sufficient","filed_date":"2021-08-05","accession":"0000950170-21-000925","full_text":"https://origin.rootz.global/static/filing/0000950170-21-000925.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"n option to extend the interest-only period to May 1, 2022 based upon the achievement of certain milestones. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, was to start upon expiration of the interest-only period and continues through October 1, 2023 (the Maturity Date). Associated with this debt facility, the Company incurred a commitment charge o","filed_date":"2021-05-06","accession":"0001564590-21-024943","full_text":"https://origin.rootz.global/static/filing/0001564590-21-024943.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"l, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Companys ability to utilize some or all its NOLs or credits could have a material adverse effect on the Companys results of operations and cash flows. Prior to December 31, 2017, the Company believes it underwent three ownership changes, however, management believes that sufficient Built-In-Gain","filed_date":"2021-05-06","accession":"0001564590-21-024943","full_text":"https://origin.rootz.global/static/filing/0001564590-21-024943.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"rector, chairman, member of a committee or chairman of a committee, as applicable. |  | |  (3) |  The initial equity grant upon election or appointment as a director shall vest in 3 equal annual installments following the grant date. |  | 17 |  |  |  | |  (4) |  Each initial equity grant shall be pro-rated for the number of whole months remaining until the anniversary of the prior years stockholders","filed_date":"2021-04-14","accession":"0001564590-21-018847","full_text":"https://origin.rootz.global/static/filing/0001564590-21-018847.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALDX","company":"Aldeyra Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":30,"context":"rapeutics, Inc.s independent registered public accounting firm for the year ending December 31, 2021. |  | |  |  | |  Proposal 3: To approve, on a non-binding, advisory basis, the compensation of our named executive officers as described in this proxy statement. |  | |  |  | |  To transact such other business as may properly come before the annual meeting or any adjournment thereof. |  | |  |  | |  These items of busine","filed_date":"2021-04-14","accession":"0001564590-21-018847","full_text":"https://origin.rootz.global/static/filing/0001564590-21-018847.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"8934eac7a5b89c8dc843c0a2bedbb50e77dbfe684d2d14173bbdc1f0111b9a6d","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"dd84be621e0f70e349db9d8794e8807c917feefb6d02bc3e1484b088ec5823ef","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":76,"hourly_limit":500,"remaining":424,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}